JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Supplement |
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
1 Roche Products Ltd, Welwyn Garden City, Herts, UK; 2 F. Hoffmann-La Roche, Basle, Switzerland; 3 F. Hoffmann-La Roche Inc, Nutley, NJ, USA
*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward{at}roche.com
Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu®) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (
1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.
Keywords: treatment , therapy , neuraminidase inhibitors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. C. Hurt, J. K. Holien, M. Parker, A. Kelso, and I. G. Barr Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation J. Virol., October 15, 2009; 83(20): 10366 - 10373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Rasmussen, D. J. Jamieson, K. MacFarlane, J. D. Cragan, J. Williams, and Z. Henderson Pandemic Influenza and Pregnant Women: Summary of a Meeting of Experts Am J Public Health, October 1, 2009; 99(S2): S248 - S254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanaka, K. Nakajima, A. Murashima, F. Garcia-Bournissen, G. Koren, and S. Ito Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women Can. Med. Assoc. J., July 7, 2009; 181(1-2): 55 - 58. [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Dharan, L. V. Gubareva, J. J. Meyer, M. Okomo-Adhiambo, R. C. McClinton, S. A. Marshall, K. St. George, S. Epperson, L. Brammer, A. I. Klimov, et al. Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States JAMA, March 11, 2009; 301(10): 1034 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Talbird, A. J. Brogan, A. P. Winiarski, and B. Sander Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States Am. J. Health Syst. Pharm., March 1, 2009; 66(5): 469 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Deyde, T. Nguyen, R. A. Bright, A. Balish, B. Shu, S. Lindstrom, A. I. Klimov, and L. V. Gubareva Detection of Molecular Markers of Antiviral Resistance in Influenza A (H5N1) Viruses Using a Pyrosequencing Method Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1039 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Russell, P. S. Kerry, D. J. Stevens, D. A. Steinhauer, S. R. Martin, S. J. Gamblin, and J. J. Skehel Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion PNAS, November 18, 2008; 105(46): 17736 - 17741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Sheu, V. M. Deyde, M. Okomo-Adhiambo, R. J. Garten, X. Xu, R. A. Bright, E. N. Butler, T. R. Wallis, A. I. Klimov, and L. V. Gubareva Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3284 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Rayner, P. Chanu, R. Gieschke, L. M. Boak, and E. N. Jonsson Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid J. Clin. Pharmacol., August 1, 2008; 48(8): 935 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Arinaminpathy and A.R McLean Antiviral treatment for the control of pandemic influenza: some logistical constraints J R Soc Interface, May 6, 2008; 5(22): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Yen, N. A. Ilyushina, R. Salomon, E. Hoffmann, R. G. Webster, and E. A. Govorkova Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo J. Virol., November 15, 2007; 81(22): 12418 - 12426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lindegardh, G. R. Davies, T. T. Hien, J. Farrar, P. Singhasivanon, N. P. J. Day, and N. J. White Importance of Collection Tube during Clinical Studies of Oseltamivir Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1835 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hatakeyama, N. Sugaya, M. Ito, M. Yamazaki, M. Ichikawa, K. Kimura, M. Kiso, H. Shimizu, C. Kawakami, K. Koike, et al. Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors JAMA, April 4, 2007; 297(13): 1435 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. M. Peiris, M. D. de Jong, and Y. Guan Avian Influenza Virus (H5N1): a Threat to Human Health Clin. Microbiol. Rev., April 1, 2007; 20(2): 243 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Moore, M. H. Chi, W. Zhou, K. Goleniewska, J. F. O'Neal, J. N. Higginbotham, and R. S. Peebles Jr. Cutting Edge: Oseltamivir Decreases T Cell GM1 Expression and Inhibits Clearance of Respiratory Syncytial Virus: Potential Role of Endogenous Sialidase in Antiviral Immunity J. Immunol., March 1, 2007; 178(5): 2651 - 2654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rameix-Welti, F. Agou, P. Buchy, S. Mardy, J. T. Aubin, M. Veron, S. van der Werf, and N. Naffakh Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3809 - 3815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zurcher, P. J. Yates, J. Daly, A. Sahasrabudhe, M. Walters, L. Dash, M. Tisdale, and J. L. McKimm-Breschkin Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro J. Antimicrob. Chemother., October 1, 2006; 58(4): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lindegardh, G. R. Davies, T. T. Hien, J. Farrar, P. Singhasivanon, N. P. J. Day, and N. J. White Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3197 - 3199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Monto, J. L. McKimm-Breschkin, C. Macken, A. W. Hampson, A. Hay, A. Klimov, M. Tashiro, R. G. Webster, M. Aymard, F. G. Hayden, et al. Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2395 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. de Jong, T. T. Thanh, T. H. Khanh, V. M. Hien, G. J.D. Smith, N. V. Chau, B. V. Cam, P. T. Qui, D. Q. Ha, Y. Guan, et al. Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection N. Engl. J. Med., December 22, 2005; 353(25): 2667 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Beigel Avian influenza A (H5N1) infection in humans. N. Engl. J. Med., September 29, 2005; 353(13): 1374 - 1385. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Bartlett and F. G. Hayden Influenza A (H5N1): Will It Be the Next Pandemic Influenza? Are We Ready? Ann Intern Med, September 20, 2005; 143(6): 460 - 462. [Full Text] [PDF]
|
|